— Corporate governance — Information policy

Information policy

According to art. 38 of the Articles of Association (on medmix.swiss/en/Investors/Governance; under Downloads), the announcements of medmix Ltd are published in the Swiss Official Journal of Commerce. In addition, notices to registered shareholders in those cases prescribed by law shall take place in writing to the shareholder’s address last known to the company.

medmix Ltd reports on its financial results every half year. In each case, it also comments on business performance and outlook. In addition, the company reports on important events on an ongoing basis (ad hoc publications). The reporting referred to in the compensation report (including the respective references to the financial reporting section) complies with the recommendations on the content of the compensation report as laid out in section 38 of annex 1 to the Swiss Code of Best Practice for Corporate Governance.

Key dates in 2022

• February 22: Annual results 2021
• April 12: Annual general meeting 2022
• July 21: Midyear results 2022

These dates and any changes can be viewed on medmix.swiss/en/Investors/Overview. Media releases (sent via e-mail) can be subscribed to on medmix.swiss/en/News/Media-Release-Subscription. Further information is available on medmix.swiss, or by contacting Investor Relations at investorrelations@medmix.com.

The contact address for Investor Relations is: 
medmix Ltd
Investor Relations
Dammstrasse 19 
6300 Zug
Switzerland
+41 (0)52 262 30 22

Material changes

On February 21, 2022, Jill Lee informed the Board of Directors of the company that she will not stand for re-election as member of the Board of Directors in 2022.

Blackout periods

Generally and regardless of whether any inside information exists or not, pursuant to medmix’ Securities Trading, Public Disclosure and Reporting Regulations, the trading in medmix Ltd securities is prohibited for (a) the members of the Board of Directors and the Executive Committee, (b) any staff reporting to any member of the Executive Committee, (c) members of Group Finance, Group Planning and M&A, Group Communications and Investor Relations, and (d) any external advisor having access to inside information in connection with medmix Ltd’s financial reporting, during the following periods: the periods starting on January 1 and July 1 until and including the trading day of the public releases of the respective full-year or half-year reports (if published prior to 7:30 am CET) or the following trading day (if published between 5:40 pm and midnight CET). In the reporting period there have not been any general blackout periods as medmix Ltd has only been incorporated on September 20, 2021.

Under certain circumstances (in particular in case of personal hardship), the company may allow exceptions to a blackout period upon reasoned request by an employee, provided that such employee is not in possession of any inside information. Such exceptions must be issued in writing with a copy to the employee’s file.